Be a China-leading, World-class, Science-driven Innovative Biotech Company
Be a China-leading, World-class, Science-driven Innovative Biotech Company
Guangdong Raynovent Biotech Co., Ltd (hereinafter referred to as "Raynovent"), is a sino-foreign joint venture focusing on the research, development and commercialization of innovative drugs in the fields of liver and respiratory diseases. Raynovent was established in October 2018, and headquarters in Guangzhou.
NEWS CENTER
The China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application of Category 1 Drug ZSP0678 for a new indication, Primary Biliary Cholangitis (PBC).
2020/03/06
News Center
Today, the gathering of CHBD was held in Shenzhen with more than 150 members in Greater Bay Area attending at the Kexing Science Park.
2020/01/10
News Center
Today, Guangdong Biopharmaceutical Innovation Technology Association Membership Conference 2019 and Innovation Forum for Pharmaceutical Enterprises under the New Situation was successfully held at the International Conference Center of Guangzhou Sunshine Hotel.
2019/12/10
News Center
Guangdong Zhongsheng Raynovent Biotechnology Co., Ltd has signed a strategic cooperation agreement with Guangdong Raffles Pharmaceutical Technology Co., Ltd and announced further in-depth cooperation in API process optimization, clinical sample preparation and new drugs commercial production.
2019/10/25
News Center
From September 11 to 12, 2019, Shenzhen International Biopharmaceutical Industry Innovation & Development Summit 2019 was successfully held at Shenzhen Yanzi Lake International Convention and Exhibition Center.
2019/09/25
News Center
Guangdong Zhongsheng Raynovent Biotechnology Co., Ltd. held the national investigators conference of phase 2 clinical trial of ZSP1273 to treat Influenza A in Guangzhou, which marked the official initiation of phase 2 trial of ZSP1273, a new drug developed by Raynovent for the treatment and prevention of influenza A and human avian influenza.
2019/08/25
News Center
The China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application of Category 1 Drug ZSP0678 for a new indication, Primary Biliary Cholangitis (PBC).
2020/03/06
News Center
Today, the gathering of CHBD was held in Shenzhen with more than 150 members in Greater Bay Area attending at the Kexing Science Park.
2020/01/10
News Center
Today, Guangdong Biopharmaceutical Innovation Technology Association Membership Conference 2019 and Innovation Forum for Pharmaceutical Enterprises under the New Situation was successfully held at the International Conference Center of Guangzhou Sunshine Hotel.
2019/12/10
News Center
Guangdong Zhongsheng Raynovent Biotechnology Co., Ltd has signed a strategic cooperation agreement with Guangdong Raffles Pharmaceutical Technology Co., Ltd and announced further in-depth cooperation in API process optimization, clinical sample preparation and new drugs commercial production.
2019/10/25
News Center
From September 11 to 12, 2019, Shenzhen International Biopharmaceutical Industry Innovation & Development Summit 2019 was successfully held at Shenzhen Yanzi Lake International Convention and Exhibition Center.
2019/09/25
News Center
Guangdong Zhongsheng Raynovent Biotechnology Co., Ltd. held the national investigators conference of phase 2 clinical trial of ZSP1273 to treat Influenza A in Guangzhou, which marked the official initiation of phase 2 trial of ZSP1273, a new drug developed by Raynovent for the treatment and prevention of influenza A and human avian influenza.
2019/08/25
News Center
JOIN US
Application To: HR@Raynovent.com
Looking forward to your joining!
Looking forward to your joining!